Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Hologic stock

Own Hologic stock in just a few minutes.

Hologic, Inc is a medical instruments & supplies business based in the US. Hologic shares (HOLX) are listed on the NASDAQ and all prices are listed in US Dollars. Hologic employs 5,814 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Hologic

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HOLX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Hologic share price

Use our graph to track the performance of HOLX stocks over time.

Hologic shares at a glance

Information last updated 2021-05-07.
52-week range$49.19 - $85.00
50-day moving average $72.48
200-day moving average $73.53
Wall St. target price$84.17
PE ratio 9.0271
Dividend yield N/A (0%)
Earnings per share (TTM) $7.28

Buy Hologic shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Hologic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Hologic under- or over-valued?

Valuing Hologic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hologic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Hologic's P/E ratio

Hologic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Hologic shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Hologic's PEG ratio

Hologic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4125. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hologic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Hologic's EBITDA

Hologic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 billion.

The EBITDA is a measure of a Hologic's overall financial performance and is widely used to measure a its profitability.

Hologic financials

Revenue TTM $5.3 billion
Operating margin TTM 47.33%
Gross profit TTM $2.5 billion
Return on assets TTM 21.16%
Return on equity TTM 64.65%
Profit margin 35.87%
Book value $14.81
Market capitalisation $16.8 billion

TTM: trailing 12 months

Shorting Hologic shares

There are currently 5.0 million Hologic shares held short by investors – that's known as Hologic's "short interest". This figure is 6% up from 4.7 million last month.

There are a few different ways that this level of interest in shorting Hologic shares can be evaluated.

Hologic's "short interest ratio" (SIR)

Hologic's "short interest ratio" (SIR) is the quantity of Hologic shares currently shorted divided by the average quantity of Hologic shares traded daily (recently around 1.7 million). Hologic's SIR currently stands at 2.99. In other words for every 100,000 Hologic shares traded daily on the market, roughly 2990 shares are currently held short.

However Hologic's short interest can also be evaluated against the total number of Hologic shares, or, against the total number of tradable Hologic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hologic's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Hologic shares in existence, roughly 20 shares are currently held short) or 0.0322% of the tradable shares (for every 100,000 tradable Hologic shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hologic.

Find out more about how you can short Hologic stock.

Hologic's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Hologic.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Hologic's total ESG risk score

Total ESG risk: 28.6

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Hologic's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 58th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Hologic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Hologic's environmental score

Environmental score: 2.95/100

Hologic's environmental score of 2.95 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Hologic's social score

Social score: 11.28/100

Hologic's social score of 11.28 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Hologic's governance score

Governance score: 8.88/100

Hologic's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Hologic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Hologic's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Hologic scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Hologic has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Hologic, Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.6
Total ESG percentile 58.02
Environmental score 2.95
Environmental score percentile 1
Social score 11.28
Social score percentile 1
Governance score 8.88
Governance score percentile 1
Level of controversy 2

Hologic share dividends

We're not expecting Hologic to pay a dividend over the next 12 months.

Have Hologic's shares ever split?

Hologic's shares were split on a 2:1 basis on 2 April 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Hologic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Hologic shares which in turn could have impacted Hologic's share price.

Hologic share price volatility

Over the last 12 months, Hologic's shares have ranged in value from as little as $49.19 up to $85. A popular way to gauge a stock's volatility is its "beta".

HOLX.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hologic's is 1.1679. This would suggest that Hologic's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Hologic overview

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site